These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 15890418)
21. [Advanced glycation end products (AGEs), free radicals and diabetes]. Gillery P J Soc Biol; 2001; 195(4):387-90. PubMed ID: 11938555 [TBL] [Abstract][Full Text] [Related]
22. Advanced glycation end-products and the progress of diabetic vascular complications. Jakus V; Rietbrock N Physiol Res; 2004; 53(2):131-42. PubMed ID: 15046548 [TBL] [Abstract][Full Text] [Related]
23. Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells. Liu Y; Ma Y; Wang R; Xia C; Zhang R; Lian K; Luan R; Sun L; Yang L; Lau WB; Wang H; Tao L Antioxid Redox Signal; 2011 Oct; 15(7):1769-78. PubMed ID: 21126209 [TBL] [Abstract][Full Text] [Related]
24. Diabetic vascular disease: it's all the RAGE. Hudson BI; Wendt T; Bucciarelli LG; Rong LL; Naka Y; Yan SF; Schmidt AM Antioxid Redox Signal; 2005; 7(11-12):1588-600. PubMed ID: 16356122 [TBL] [Abstract][Full Text] [Related]
25. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S Horm Metab Res; 2011 Sep; 43(10):731-4. PubMed ID: 21932180 [TBL] [Abstract][Full Text] [Related]
26. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications. Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291 [TBL] [Abstract][Full Text] [Related]
27. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Ramasamy R; Yan SF; Schmidt AM Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677 [TBL] [Abstract][Full Text] [Related]
28. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Yamagishi S; Nakamura K; Matsui T Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657 [TBL] [Abstract][Full Text] [Related]
29. Differences Between Tg2576 and Wild Type Mice in the NMDA Receptor-Nitric Oxide Pathway After Prolonged Application of a Diet High in Advanced Glycation End Products. Kristofikova Z; Ricny J; Sirova J; Ripova D; Lubitz I; Schnaider-Beeri M Neurochem Res; 2015 Aug; 40(8):1709-18. PubMed ID: 26189181 [TBL] [Abstract][Full Text] [Related]
30. Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. Stefano GB; Challenger S; Kream RM Eur J Nutr; 2016 Dec; 55(8):2339-2345. PubMed ID: 27084094 [TBL] [Abstract][Full Text] [Related]
32. The protective effect of Smilax glabra extract on advanced glycation end products-induced endothelial dysfunction in HUVECs via RAGE-ERK1/2-NF-κB pathway. Sang HQ; Gu JF; Yuan JR; Zhang MH; Jia XB; Feng L J Ethnopharmacol; 2014 Aug; 155(1):785-95. PubMed ID: 24953033 [TBL] [Abstract][Full Text] [Related]
33. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Rojas A; Morales MA Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904 [TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941 [TBL] [Abstract][Full Text] [Related]
35. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Yamagishi S Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478 [TBL] [Abstract][Full Text] [Related]
36. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998 [TBL] [Abstract][Full Text] [Related]
37. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639 [TBL] [Abstract][Full Text] [Related]
38. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Zhong Y; Li SH; Liu SM; Szmitko PE; He XQ; Fedak PW; Verma S Hypertension; 2006 Sep; 48(3):504-11. PubMed ID: 16847147 [TBL] [Abstract][Full Text] [Related]
39. Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Ando R; Ueda S; Yamagishi S; Miyazaki H; Kaida Y; Kaifu K; Yokoro M; Nakayama Y; Obara N; Fukami K; Takeuchi M; Okuda S Diab Vasc Dis Res; 2013 Sep; 10(5):436-41. PubMed ID: 23766377 [TBL] [Abstract][Full Text] [Related]